Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Nobel Laboratories, LLC
WARNING LETTER
•Nobel Laboratories, LLC

Nobel Laboratories, LLC – FDA Warning Letter

Record Details

The FDA issued a Warning Letter to Fasprin Health, LLC / Nobel Laboratories, LLC for marketing "FASPRIN?" as an unapproved new drug and for misbranding.

Fasprin, an OTC internal analgesic with aspirin (81mg), glucosamine, zinc salt, and magnesium salt, is deemed a "new drug" because its labeling claims extend beyond pain/fever relief to include cardiovascular disease prevention (heart attack, stroke, DVT), arthritis treatment, blood pressure reduction, and prevention of Alzheimer's, Parkinson's, colon cancer, periodontal disease, vision loss, and gallstones, as well as promoting longevity. These uses, the combination of active ingredients, and the 81mg dosage are not generally recognized as safe and effective, nor are they covered by the OTC Drug Review or an approved New Drug Application (NDA).

Furthermore, Fasprin's quick-dissolving, mouth-absorbed dosage form is not generally recognized as safe and effective, requiring an approved NDA.

The product is also misbranded due to: * Lack of adequate directions for its intended cardiovascular and arthritis uses, which require professional supervision. * Absence of a "Uses" section as required by 21 CFR § 201.66(c)(4). * Inadequate dosage for pain/fever relief compared to OTC Drug Review standards. * Misleading labeling ("Daily Aspirin Regimen") contradicting

Company
Nobel Laboratories, LLC
Product type
Drugs
Office
Dallas District Office
People
  • Sherrie L. Krolczyk
  • Reynaldo Rodriguez (District Director)
View Company Profile

ID · 91762ade-a9d1-46bb-8979-5e4411458cfb

Violation Codes10
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)21 CFR 343.8021.U.S.C. 355(a)21 CFR 201.66(b)(2)21 U.S.C. 352(f)(1)21 CFR 201.521 U.S.C. 352(a)21 U.S.C. 352(f)(2)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Nobel Laboratories, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.